In vitro

Global Immunochemistry Analyzers Market 2015-2030 Featuring Roche, Danaher, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Labs, and Abbott Labs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 12, 2020
Health, Infectious diseases, Economy, Articles, Finance, Business process, Market analysis, Market research, In vitro, Economic model, Impact of the COVID-19 pandemic, Market trend

The "Immunochemistry Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunochemistry Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.
  • The market model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • This model discusses in detail the impact of COVID-19 on Immunochemistry Analyzers market for the year 2020 and beyond.
  • Annualized total Immunochemistry Analyzers market revenue by segment and market outlooks from 2015-2030.

BCR-ABL Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

Retrieved on: 
Monday, August 3, 2020
Philadelphia chromosome, BCR, ABL, Market segmentation, Market analysis, In vitro, Branches of biology, Biology

BCR-ABL Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Key Points: 
  • BCR-ABL Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • - Annualized total BCR-ABL Tests market revenue by segment and market outlooks from 2015-2030.
  • This model is required reading for -
    - CMO executives who must have deep understanding of the BCR-ABL Tests market place to make strategic planning and investment decisions.
  • - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BCR-ABL Tests market in the future.

ALK Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

Retrieved on: 
Monday, August 3, 2020
Business process, Market analysis, Market research, Market segmentation, Anaplastic lymphoma kinase, In vitro, ALK

ALK Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Key Points: 
  • ALK Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • - Annualized total ALK Tests market revenue by segment and market outlooks from 2015-2030.
  • This model is required reading for -
    - CMO executives who must have deep understanding of the ALK Tests market place to make strategic planning and investment decisions.
  • - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALK Tests market in the future.

Curi Bio Acquires Dana Solutions

Retrieved on: 
Thursday, July 23, 2020
Hardware, FDA, Data management, Technology, Nanotechnology, Stem cells, Pharmaceutical, General Health, Genetics, Clinical trials, Cardiology, Science, Software, Other Science, Research, Health, Alternatives to animal testing, Curi, In vitro

Curi Bio , a leading developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays.

Key Points: 
  • Curi Bio , a leading developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays.
  • Curi Bio is developing human-relevant platforms integrating human cells, systems, and data to accelerate the discovery of new medicines, said Curi CEO Michael Cho.
  • Curi and Dana will continue the FDA project following the acquisition.
  • Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines.

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Retrieved on: 
Tuesday, July 21, 2020
Alternatives to animal testing, In vitro

The collaboration agreement provides that all rights, title and interest in all results shall be owned by CalciMedica.

Key Points: 
  • The collaboration agreement provides that all rights, title and interest in all results shall be owned by CalciMedica.
  • ), analysis of signal transduction pathways (such as Ca2+ and cAMP signalling) and in vitro and in vivo disease modelling.
  • The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications.
  • It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.

Frost & Sullivan Reveals Top Five Predictions for the Global Healthcare Industry Post COVID-19

Retrieved on: 
Thursday, July 16, 2020
IVD, In vitro

"While the life sciences segment seems to be surviving and thriving, in certain scenarios, medical technologies and imaging are expected to be hit the hardest.

Key Points: 
  • "While the life sciences segment seems to be surviving and thriving, in certain scenarios, medical technologies and imaging are expected to be hit the hardest.
  • Traditional models of in vitro diagnostics (IVD) testing in a healthcare setting are unable to meet unprecedented demand.
  • By the end of 2020, 33% of global clinical trials will be disrupted, putting $3 billion in new product revenues at risk.
  • Post-Pandemic Global Healthcare Market Outlook, 2020is part of Frost & Sullivan's global Transformational Health Growth Partnership Service program.

Frost & Sullivan Reveals Top Five Predictions for the Global Healthcare Industry Post COVID-19

Retrieved on: 
Thursday, July 16, 2020
IVD, In vitro

"While the life sciences segment seems to be surviving and thriving, in certain scenarios, medical technologies and imaging are expected to be hit the hardest.

Key Points: 
  • "While the life sciences segment seems to be surviving and thriving, in certain scenarios, medical technologies and imaging are expected to be hit the hardest.
  • Traditional models of in vitro diagnostics (IVD) testing in a healthcare setting are unable to meet unprecedented demand.
  • By the end of 2020, 33% of global clinical trials will be disrupted, putting $3 billion in new product revenues at risk.
  • Post-Pandemic Global Healthcare Market Outlook, 2020is part of Frost & Sullivan's global Transformational Health Growth Partnership Service program.

Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

Retrieved on: 
Wednesday, July 15, 2020
Viruses, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, In vitro, Medicine, Animal virology

The preliminary study results show that AT-301 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which is the standard disease model used for initial screening of COVID-19 drug candidates.

Key Points: 
  • The preliminary study results show that AT-301 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which is the standard disease model used for initial screening of COVID-19 drug candidates.
  • The purpose of these experiments was to mimic the viruss entry process in vitro by examining the infectivity of VERO monkey kidney cells by authentic SARS-CoV-2 virus particles.
  • The cells were then fixed with 10% formalin overnight and then the cells were permeabolized with 0.5% Triton X-100.
  • The in vitro laboratory testing was conducted under contract at a leading academic research center that specializes in infectious disease research.

Global In Vitro Diagnostics (IVD) Quality Control Market to 2026 - Industry Analysis, Trends, Market Size, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, July 13, 2020
Medical devices, Health, IVD, Forecasting, In vitro, Business process, Science, Scientific method

The "In Vitro Diagnostics (IVD) Quality Control Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Diagnostics (IVD) Quality Control Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global in vitro diagnostics (IVD) quality control market provides qualitative and quantitative analysis for the period from 2018 to 2026.
  • The report predicts the global in vitro diagnostics (IVD) quality control market to grow with a CAGR of 3.5% over the forecast period from 2020-2026.
  • The report on in vitro diagnostics (IVD) quality control market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global in vitro diagnostics (IVD) quality control market over the period of 2018 to 2026.

Neuro-Sys SAS Launches Innovative In Vivo Services in CNS/PNS Field

Retrieved on: 
Tuesday, June 30, 2020
Alternatives to animal testing, In vitro, Vivo, In vivo, Economy of China, Companies of China, Companies

Of this latest development Chief Scientific Officer Noelle Callizot said: ''We continue to conduct research to refine our knowledge of the pathological pathways and to develop our innovative in vitro models.

Key Points: 
  • Of this latest development Chief Scientific Officer Noelle Callizot said: ''We continue to conduct research to refine our knowledge of the pathological pathways and to develop our innovative in vitro models.
  • At the same time, it's important that our in vivo activity validates and enhances our in vitro work, allowing our customers a seamless process in their drug development programmes.''
  • The significant investment completes a record year for Neuro-Sys' in vivo business, with turnover increasing by 60% over the previous year.
  • Neuro-Sys develops specific preclinical in vitro and in vivo models of CNS and PNS diseases.